Phase Ib study of combinations of avadomide (CC‐122), CC‐223, CC‐292, and rituximab in patients with relapsed/refractory diffuse large B‐cell lymphoma

There is a need for additional treatment options for patients with relapsed or refractory diffuse large B‐cell lymphoma (DLBCL) who do not benefit from available therapies. We examined combinations of the cereblon E3 ligase modulator (CELMoD) agent avadomide (CC‐122), the selective, ATP‐competitive...

Descripción completa

Detalles Bibliográficos
Autores principales: Ribrag, Vincent, Chavez, Julio C., Boccomini, Carola, Kaplan, Jason, Chandler, Jason C., Santoro, Armando, Corradini, Paolo, Flinn, Ian W., Advani, Ranjana, Cassier, Philippe A., Sangha, Randeep, Kenkre, Vaishalee P., Isufi, Iris, Uttamsingh, Shailaja, Hagner, Patrick R., Gandhi, Anita K., Shen, Frank, Michelliza, Sophie, Haeske, Harald, Hege, Kristen, Pourdehnad, Michael, Kuruvilla, John
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Haematologic Malignancy ‐ Lymphoid
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9176062/
https://www.ncbi.nlm.nih.gov/pubmed/35846221
http://dx.doi.org/10.1002/jha2.375

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9176062/
https://www.ncbi.nlm.nih.gov/pubmed/35846221
http://dx.doi.org/10.1002/jha2.375

Ejemplares similares